Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis
Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis
复制标题
DOI：
10.1159/000455842
复制
发表时间：
2017-01-01
影响因子：
2.4
通讯作者：
Sun, Gaoling
中科院分区：
文献类型：
--
作者：
Feng, Enshan;Sui, Changbai;Sun, Gaoling
背景/目的：目前的荟萃分析评估了新诊断的胶质母细胞瘤患者单纯放疗(RT)和放疗+替莫唑胺(TMZ)治疗后的生存结果。方法：通过在Medline、Current Contents和Cochrane数据库中广泛检索相关文献，由2位独立的评价者使用术语“多形性胶质母细胞瘤/胶质母细胞瘤，TMZ，放射治疗/放疗和生存”来确定相关研究。结果：结果显示，联合治疗组的中位生存期为13.41-19个月，而单纯RT组的中位生存期为7.7-17.1个月。两组患者的无进展生存期(PFS)也有显著差异(RT+TMZ为6.3~13个月，单纯RT为5~7.6个月)。RT+TMZ组和RT组的6个月生存率和6个月PFS率无显著差异(合并OR分别为0.690和0.429，p=0.052)，但1年生存率和1年PFS率有显著差异(OR分别为0.469；p=0.030和OR 0.245，p<；0.001)。结论：同期RT+TMZ治疗初诊脑胶质母细胞瘤疗效较好，可改善患者的总体生存率和无瘤生存率。(C)2017年S.Karger AG，巴塞尔
Background/Aim: The current meta-analysis evaluated the survival outcomes of newly diagnosed glioblastoma patients treated with radiotherapy (RT) alone and with RT + temozolomide (TMZ). Methods: Relevant studies were identified byan extensive literature search in Medline, Current Contents and Cochrane databases by 2 independent reviewers using the terms "glioblastoma multiforme/glioblastoma, TMZ, radiation therapy/RT and survival." Results: Results revealed a median survival of 13.41-19 months in the combined treatment group, as opposed to 7.7-17.1 months in the RT-alone group. Progression-free survival (PFS) was also significantly different between the 2 groups (RT + TMZ, 6.3-13 months; RT-alone, 5-7.6 months). While there was no significant difference in the 6-month survival and 6-month PFS rates between the RT + TMZ and RT groups (pooled OR 0.690; p = 0.057 and OR 0.429, p = 0.052, respectively), the 1-year survival and 1-year PFS rates showed significant difference (OR 0.469; p = 0.030 and OR 0.245, p < 0.001, respectively). Conclusions: Concomitant RT + TMZ is more effective and improves the overall survival and PFS in patients with newly diagnosed glioblastoma. (C) 2017 S. Karger AG, Basel